Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/Health Canada/JETREA

Authorized

STANDARD

JETREA

thrombogenics nv🇨🇦 Health Canada

Approval Date: Jul 4, 2025
Approval ID: efee6d64bfe9ca93
Company: thrombogenics nv
Type: Standard

Approval Details

Approval Id: efee6d64bfe9ca93
Drug Approval Canada Name: JETREA
Product Name: JETREA
Status: Cancelled Post Market
Status Date: 2020-03-20
Original Market Date: 2019-05-08
Din: 02452154
Drug Class: Human
Dosage Form: Solution
Route Of Administration: Intravitreal
Schedule: Schedule D
Ahfs: 52:44.00
Atc Original: S01XA22 OCRIPLASMIN
Atc Name: s 01 xa 22
Aig Number: 0154610002
Company Name: thrombogenics nv
Company Address: Gaston Geenslaan 1, Leuven, Flemish Brabant, Belgium, 3001

Active Ingredients

OCRIPLASMIN

1.25 MG / ML

Authorized

Quick Info

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

efee6d64bfe9ca93

Type

Standard

Back to Health Canada Approvals

JETREA - Health Canada Drug Approval Details